WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 208227
Description: S007-1558 is viable GPVI modulator
MedKoo Cat#: 208227
Chemical Formula: C19H19N3O4S
Exact Mass: 385.1096
Molecular Weight: 385.44
Elemental Analysis: C, 59.21; H, 4.97; N, 10.90; O, 16.60; S, 8.32
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: S0071558, S0-07-1558, S007-15-58, S007-1558 (S); GPVI modulator 5
IUPAC/Chemical Name: (S)-2-((4-Methoxyphenyl)sulfonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxamide
InChi Key: KBVPHVCPUVDXOQ-SFHVURJKSA-N
InChi Code: InChI=1S/C19H19N3O4S/c1-26-12-6-8-13(9-7-12)27(24,25)22-11-17-15(10-18(22)19(20)23)14-4-2-3-5-16(14)21-17/h2-9,18,21H,10-11H2,1H3,(H2,20,23)/t18-/m0/s1
SMILES Code: O=C([C@@H]1CC2=C(CN1S(=O)(C3=CC=C(OC)C=C3)=O)NC4=C2C=CC=C4)N
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 385.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Saxena A, Valicherla GR, Jain GK, Bhatta RS, Saxena AK, Gayen JR. Metabolic profiling of a novel antithrombotic compound, S002-333 and enantiomers: metabolic stability, species comparison and in vitro-in vivo extrapolation. Biopharm Drug Dispos. 2016 May;37(4):185-99. doi: 10.1002/bdd.1995. PMID: 26477787.
2: Saxena A, Jain GK, Siddiqui HH, Bhunia SS, Saxena AK, Gayen JR. In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies. Xenobiotica. 2014 Apr;44(4):295-308. doi: 10.3109/00498254.2013.831958. Epub 2013 Aug 30. PMID: 23992115.
3: Saxena A, Valicherla GR, Joshi P, Saxena R, Cheruvu SH, Bhunia SS, Jain GK, Siddiqui HH, Saxena AK, Gayen JR. Pharmacokinetics, dose proportionality and permeability of S002-333 and its enantiomers, a potent antithrombotic agent, in rabbits. Xenobiotica. 2015;45(11):1016-23. doi: 10.3109/00498254.2015.1034224. Epub 2015 Jun 18. PMID: 26084373.
4: Bhateria M, Rachumallu R, Yerrabelli S, Saxena AK, Bhatta RS. Insight into stereoselective disposition of enantiomers of a potent antithrombotic agent, S002-333 following administration of the racemic compound to mice. Eur J Pharm Sci. 2017 Apr 1;101:107-114. doi: 10.1016/j.ejps.2017.02.012. Epub 2017 Feb 9. PMID: 28189817.
5: Bhateria M, Ramakrishna R, Puttrevu SK, Saxena AK, Bhatta RS. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6. Chem Biol Interact. 2016 Aug 25;256:257-65. doi: 10.1016/j.cbi.2016.07.001. Epub 2016 Jul 4. PMID: 27387538